Healthcare Industry News: HSMN NewsFeed
News Release - October 17, 2017
Menlo Therapeutics Expands its Management TeamREDWOOD CITY, Calif., Oct. 17, 2017 -- (Healthcare Sales & Marketing Network) -- Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to advance serlopitant into later stages of development, today announced key additions to its management team including:
- Kristine M. Ball, SVP of Corporate Strategy and Chief Financial Officer. Ms. Ball joined Menlo Therapeutics with approximately 25 years of experience in the life-sciences industry. Most recently, Ms. Ball served as Senior Vice President and Chief Financial Officer of Relypsa, Inc., where she raised over $675 million in various equity and debt financings and played a key role in executing two pharmaceutical partnerships and the company's acquisition by Galenica for over $1.5 billion. Prior to Relypsa, Ms. Ball was Senior Vice President of Finance and Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc.
Serlopitant is a once-daily NK1 receptor antagonist being developed for the treatment of pruritus, or itch, associated with atopic dermatitis, psoriasis, and prurigo nodularis. Serlopitant is also being evaluated as a potential treatment option for refractory chronic cough, a cough for which a treatable cause cannot be found. Menlo Therapeutics has completed two Phase 2 studies with serlopitant showing a statistically significant reduction in pruritus compared to placebo. Originally developed by Merck and licensed to Menlo Therapeutics in 2012, serlopitant has been evaluated in more than 1,000 patients and has been shown to be well-tolerated, including in patients who have received treatment for up to a year. Serlopitant is an investigational drug that is not currently approved for use in any indication.
About Menlo Therapeutics Inc.
Menlo Therapeutics Inc. is a privately held late stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatological conditions and refractory chronic cough. The company has initiated a broad clinical development program for serlopitant including Phase 2 studies for the treatment of pruritus associated with atopic dermatitis, pruritus associated with psoriasis, and refractory chronic cough, and expects to start Phase 3 trials for the treatment of pruritus associated with prurigo nodularis in the first half of 2018. Menlo Therapeutics has worldwide rights to serlopitant, excluding Japan where Menlo Therapeutics has licensed serlopitant to JT Torii. Menlo is funded by leading healthcare investors. More information is available at www.menlotherapeutics.com.
Source: Menlo Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.